Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada

Kassem Bourgi(Nashville Oncology Associates), John R. Koethe(Vanderbilt University Medical Center), Joseph B. Margolick(Johns Hopkins University), Stephen J. Gange(Johns Hopkins University), Michael J. Silverberg(Kaiser Permanente), Peter F. Rebeiro(Vanderbilt University Medical Center), Keri N. Althoff(Bloomberg (United States)), Jun Li(Centers for Disease Control and Prevention), Amanda L. Willig(American Sports Medicine Institute), Viviane D. Lima(St. Paul's Hospital), Bryan E. Shepherd(Vanderbilt University), Heidi M. Crane(University of Washington), Jordan E. Lake(The University of Texas Health Science Center at Houston), Michael A. Horberg(Kaiser Permanente), M. John Gill(University of Calgary), William C. Mathews(Northwestern University), Gregory D. Kirk(Uganda Cancer Institute), Richard D. Moore(Johns Hopkins University), Timothy R. Sterling(Vanderbilt University Medical Center), Frank J. Palella(Northwestern University), Cherise Wong(Pfizer (United States)), Charles S. Rabkin(National Cancer Institute), Jennifer E. Thorne(Johns Hopkins University), Cathy A. Jenkins(Vanderbilt University)
Journal of the International AIDS Society
April 1, 2020
Cited by 242


Related Papers